Clinical Trial

Lipid Balance in Adult Sickle Cell Patients

Study acronym: HDL2
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to describe and/or searches for, in cohorts of adult sickle cell anemia (SCA) and SC sickle cell patients living in the French West Indies and followed by SCD Reference and Competence Centers: 1-lipids profiles and associations at steady state with occurrence of sickle cell disease (SCD) complications, 2-lipids profile evolution during and after prospective acute complications (vasoocclusive crises (VOC) and priapism), 3-lipids profile variation (inter /intra individuals) during 4 prospective years, 4- Genetic primary modulators of SCD complications, 5- insulin resistance (HOMA), free fatty acids and glycerol dosages, 6- lipids enzymes, lipidome and functionality of HDL in sub-groups of SCD population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-21.
Status change: Recruiting → Active, Not Recruiting 2025-12-03
Trial Details
NCT Number NCT05780775
Lead Sponsor Centre Hospitalier Universitaire de la Guadeloupe
Collaborators: Direction Générale de l'Offre de Soins
Conditions Sickle Cell Disease, Dyslipidemia, Complication
Enrollment 116 participants
Start Date 2022-11-30
Primary Completion 2027-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-10